Literature DB >> 24651586

[Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea].

Jun Heo1, Seong Woo Jeon.   

Abstract

Although, the prevalence of Helicobacter pylori infection in Korea has declined owing to the eradication therapy, recent seropreva-lence of H. pylori infection is still reported to be as high as 54.4%. Until now, "standard regimen" for eradication of H. pylori has been conventional triple therapy consisting of proton pump inhibitor, amoxicillin, and clarithromycin. However, with the increase in antibiotic resistance, especially against clarithromycin, the eradication rate of conventional triple therapy has steadily declined during the past 13 years in Korea. Present eradication rate of standard triple therapy is reported to be less than 80%, which is the Maginot line of efficacy for the currently available regimen. Therefore, new first line eradication regimen is needed to enhance the eradication rate of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24651586     DOI: 10.4166/kjg.2014.63.3.141

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  7 in total

1.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.

Authors:  Hyun Jeong Lee; Jin Il Kim; Jin Soo Lee; Eun Jung Jun; Jung-Hwan Oh; Dae Young Cheung; Woo Chul Chung; Byung-Wook Kim; Sung Soo Kim
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

3.  Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects.

Authors:  Hyeonsoo Park; Choon Ok Kim; Mikyung Kim; Yeji Lim; Woo Yul Lee; Sukyong Yoon; Min Soo Park
Journal:  Transl Clin Pharmacol       Date:  2020-09-23

4.  Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.

Authors:  Ayse Kefeli; Sebahat Basyigit; Abdullah Ozgur Yeniova; Tarık Tayfur Kefeli; Muzaffer Aslan; Ozlem Tanas
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

5.  The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body.

Authors:  Ji Won Seo; Jae Yong Park; Tae-Seop Shin; Jae Gyu Kim
Journal:  BMC Gastroenterol       Date:  2019-08-07       Impact factor: 3.067

6.  Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.

Authors:  Joon Sung Kim; Byung-Wook Kim; Su Jin Hong; Jin Il Kim; Ki-Nam Shim; Jie-Hyun Kim; Gwang Ho Baik; Sang Wook Kim; Hyun Joo Song; Ji Hyun Kim
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519

7.  Peptide Nucleic Acid Probe-Based Analysis as a New Detection Method for Clarithromycin Resistance in Helicobacter pylori.

Authors:  Da Hyun Jung; Jie-Hyun Kim; Su Jin Jeong; Soon Young Park; Il-Mo Kang; Kyoung Hwa Lee; Young Goo Song
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.